Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Gains from Investment Securities (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Gains from Investment Securities readings, the most recent being -$18000.0 for Q4 2017.

  • On a quarterly basis, Gains from Investment Securities fell 63.64% to -$18000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was -$29000.0, a 120.71% decrease, with the full-year FY2025 number at $5000.0, up 100.02% from a year prior.
  • Gains from Investment Securities hit -$18000.0 in Q4 2017 for Eledon Pharmaceuticals, down from -$11000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $2.1 million in Q4 2014 to a low of -$18000.0 in Q4 2017.
  • Median Gains from Investment Securities over the past 5 years was $184708.5 (2014), compared with a mean of $601910.0.
  • Biggest five-year swings in Gains from Investment Securities: surged 90.99% in 2014 and later tumbled 63.64% in 2017.
  • Eledon Pharmaceuticals' Gains from Investment Securities stood at $1.1 million in 2013, then skyrocketed by 90.99% to $2.1 million in 2014, then plummeted by 92.97% to $151000.0 in 2015, then tumbled by 107.28% to -$11000.0 in 2016, then crashed by 63.64% to -$18000.0 in 2017.
  • The last three reported values for Gains from Investment Securities were -$18000.0 (Q4 2017), -$11000.0 (Q4 2016), and $151000.0 (Q3 2015) per Business Quant data.